Tofacitinib in Recurrent GBM Patients
| 対象疾患 | Glioblastoma |
|---|---|
| 相 | 第3相 |
| スポンサー | University of Texas Southwestern Medical Center |
| ステータス | 完了 |
| 参加者数 | 18 名 |
| 介入（薬剤） | Tofacitinib 10mg, Temozolomide, Lomustine |
| 開始日 | 2022年10月7日 |
| 完了日 | 2025年2月18日 |
| 結果公開日 | 2026年6月29日 |
概要
The purpose of this study is to examine the effects of Tofacitinib in patients with recurrent Glioblastoma.
Progression-free Survival (PFS) of the Study Cohort as Defined by RANO Criteria.
| Newly Diagnosed or Recurrent Off Temozolomide | 4 months |
|---|---|
| Recurrent Disease on Temozolomide | 4 months |
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma — Wake Forest University Health Sciences
- Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblast — National Cancer Institute (NCI)
- TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma — National Cancer Institute (NCI)
- Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant G — City of Hope Medical Center
- Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma — L. Nicolas Gonzalez Castro, MD, PhD
- A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care — Bryan Allen